The present invention relates to novel, non-secosteroidal, phenyl-benzofuran compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1.alpha.,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
This application is submitted as a United States national phase entry, pursuant to 35 U.S.C. .sctn.371, of PCT/US2004/035529, filed on 16 Nov. 2004, which claims the benefit of U.S. provisional patent application Ser. No. 60/523,905, filed 20 Nov. 2003, which is incorporated by reference herein.
